- Home
- DOYU vs NBTX Comparison
DOYU vs NBTX Comparison
Compare DOYU & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOYU
- NBTX
- Stock Information
- Founded
- DOYU 2014
- NBTX 2003
- Country
- DOYU China
- NBTX France
- Employees
- DOYU N/A
- NBTX N/A
- Industry
- DOYU Computer Software: Programming Data Processing
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- DOYU Technology
- NBTX Health Care
- Exchange
- DOYU Nasdaq
- NBTX Nasdaq
- Market Cap
- DOYU 195.9M
- NBTX 211.9M
- IPO Year
- DOYU 2019
- NBTX 2020
- Fundamental
- Price
- DOYU $7.86
- NBTX $6.67
- Analyst Decision
- DOYU Hold
- NBTX Strong Buy
- Analyst Count
- DOYU 1
- NBTX 1
- Target Price
- DOYU $7.00
- NBTX $8.00
- AVG Volume (30 Days)
- DOYU 78.5K
- NBTX 7.4K
- Earning Date
- DOYU 09-11-2025
- NBTX 09-17-2025
- Dividend Yield
- DOYU 249.36%
- NBTX N/A
- EPS Growth
- DOYU N/A
- NBTX N/A
- EPS
- DOYU N/A
- NBTX N/A
- Revenue
- DOYU $575,786,186.00
- NBTX N/A
- Revenue This Year
- DOYU N/A
- NBTX N/A
- Revenue Next Year
- DOYU N/A
- NBTX $221.06
- P/E Ratio
- DOYU N/A
- NBTX N/A
- Revenue Growth
- DOYU N/A
- NBTX N/A
- 52 Week Low
- DOYU $5.68
- NBTX $2.76
- 52 Week High
- DOYU $20.17
- NBTX $7.29
- Technical
- Relative Strength Index (RSI)
- DOYU 48.90
- NBTX 66.43
- Support Level
- DOYU $8.45
- NBTX $6.49
- Resistance Level
- DOYU $9.34
- NBTX $7.15
- Average True Range (ATR)
- DOYU 0.51
- NBTX 0.36
- MACD
- DOYU -0.04
- NBTX 0.11
- Stochastic Oscillator
- DOYU 12.13
- NBTX 73.88
About DOYU DouYu International Holdings Limited ADS
DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company operates its platform on both PC and mobile apps, through which users can enjoy immersive and interactive games and entertainment live streaming. It generates revenues through live streaming and advertisement.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.